7 Β –amino-3- [4-pyridyl-2-thiazole Sulfur Radical ]-3-cephem CAS 400827-64-7

Product Description:

Product Name: 7 β –amino-3- [4-pyridyl-2-thiazole sulfur radical ]-3-cephem CAS NO:400827-64-7

Synonyms:

Pyridinium, 4-[2-[[(6R,7R)-7-amino-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]thio]-4-thiazolyl]-1-methyl-, chloride, hydrochloride (1:1:1)

4-(2-{[(6R,7R)-7-Amino-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]sulfanyl}-1,3-thiazol-4-yl)-1-methylpyridinium chloride hydrochloride (1:1:1)

Chemical & Physical Properties:

Appearance : Light yellow solid.

Assay : ≥99.0%

The mother nucleus of cefalolin is the main raw material for the synthesis of cefalolin axetil. The antibacterial mechanism of cefalolin axetil is to combine with penicillin binding protein, and then play a bactericidal role. It has strong antibacterial activity to gram-positive anaerobe, Staphylococcus aureus, Streptococcus pneumoniae, gram-negative anaerobe, MRSA and other resistant Gram-positive bacteria, and also has inhibitory effect on Escherichia coli, Haemophilus influenzae, penicillin resistant pneumococcus, Klebsiella acidogenes and Klebsiella pneumoniae. Ceftazidime was developed by Takeda pharmaceutical company of Japan, and the US Forest laboratories was authorized by the market. Like other cephalosporins, a double ring and four β - lactam rings combine to form a cephalosporin ring. The activity of cefalolin to MRSA is due to its 1,3-thionitrogen chemical Book heterocyclic ring. Cephalosporin is the latest generation of cephalosporin. Phase III clinical trials show that it has strong antibacterial activity against MRSA. The control experiments show that in the treatment of MRSA, there is no significant difference in the therapeutic effect of combination of cephalosporin with vancomycin and aztreonam. In the treatment of small area acquired pneumonia, cefalolin has the same therapeutic effect as ceftriaxone, and has no more side effects. In October 2010, the U.S. FDA approved the launch of a new cephalosporin injection antibiotic teflaro developed by Takeda pharmaceutical, Japan, for the treatment of adult community-acquired bacterial pneumonia (CaBP) and acute bacterial skin and skin structural infection (absssi), including methicillin-resistant Staphylococcus aureus (MRSA).

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.